-
1 week ago | 
benzinga.com | Meg Flippin
Glucotrack Inc. GCTK will host a virtual webinar on Thursday, May 29, from 11 a.m. to 12 p.m. ET to discuss its Continuous Blood Glucose Monitor (CBGM) technology, a potentially game-changing medical device that could reshape how diabetes is managed. Experts from the Rutherford, New Jersey medical technology company will lead the session, providing a deep dive into how CBGM technology works and how it can transform the lives of people suffering from diabetes.
-
1 week ago | 
benzinga.com | Meg Flippin
Lottery.com Inc., LTRY a technology company on a mission to transform how, where and when lottery is played, is taking its expertise to the next level, recently announcing a $10 million deal to purchase a majority stake in DotCom Ventures Inc., which owns Concerts.com and TicketStub.com.
-
1 week ago | 
benzinga.com | Meg Flippin
Ascent Solar Technologies ASTI, the maker of featherweight, flexible and durable CIGS thin-film photovoltaic (PV) solutions and a growing supplier to the space market, inked a Master Services Agreement with NOVI Space Inc., a space company that makes and operates AI-powered satellites. Under the terms of the deal, Ascent Solar is providing NOVI with rollable PV array blankets so that the company can deliver real-time Earth Observation (EO) insights directly from space.
-
1 week ago | 
benzinga.com | Meg Flippin
SeaStar Medical Holding Corporation ICU, a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, is seeing double-digit growth in sales of QUELIMMUNE, which drove revenues for the company in the first quarter of 2025.
-
1 week ago | 
benzinga.com | Meg Flippin
The idea of vehicles communicating with each other and with roadside infrastructure is no longer in the conceptual stage. It's beginning to be deployed on the ground as cities, municipalities and government agencies around the world look for ways to enhance safety and reduce traffic congestion. After all, connected vehicle (CV) technology enables vehicles to share information about driving conditions, traffic and accidents in real-time.
-
1 week ago | 
benzinga.com | Meg Flippin
TNL Mediagene TNMG, the next-gen media company focused on Millennial and Gen Z audiences in Japan and Taiwan that leverages its AI-powered data to offer its client base of over 850 regional and global advertisers an innovative and effective way to reach this audience, is getting noticed by Wall Street. Benchmark Equity Research recently initiated coverage of TNL MEdiagene with a speculative buy rating and set a $3.50 per share price target, implying nearly 350% growth in the stock.
-
1 week ago | 
benzinga.com | Meg Flippin
Next-generation immunotherapy cancer drug company Indaptus Therapeutics Inc. INDP narrowed its loss and hit key milestones during Q1 as it advanced its quest to exploit bacteria's natural ability to activate both innate and adaptive cellular immune pathways to fight cancer. For the quarter ending Mar.
-
2 weeks ago | 
benzinga.com | Meg Flippin
Brett Richards, CEO and executive director of Pasofino Gold Ltd. EFRGF, was recently a guest on Benzinga's All-Access. Pasofino Gold is a Canadian mining company laser-focused on building out its 400 million ounce Dugbe Gold Project in Liberia. The company is in the process of updating its feasibility study, which was done three years ago, and expects it to be completed in no more than nine months. A lot has changed since then.
-
2 weeks ago | 
benzinga.com | Meg Flippin
Paul Mann, CEO of ASP Isotopes Inc. ASPI and Stefano Marani, CEO of Renergen Ltd. RGNNF, were recently guests on Benzinga's All-Access. The two CEOs sat down with Benzinga to discuss their recently announced merger transaction. ASP Isotopes, which is a materials company focused on the production of isotopes for use in multiple industries, from medical diagnosis and treatments to industrial applications, entered into a merger agreement with Renergen, the South African helium and LNG producer.
-
2 weeks ago | 
benzinga.com | Meg Flippin
Cognition Therapeutics Inc. CGTX, a clinical-stage company developing drugs that treat neurodegenerative disorders, can add a third indication, dry age-related macular degeneration or dry AMD, to the diseases that its experimental drug zervimesine (CT1812) may be able to treat. The company just reported positive topline results of its MAGNIFY Phase 2 clinical trial of zervimesine in adults with geographic atrophy (GA) secondary to dry AMD.
